Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPROGRAM-02
2024-516709-22-00Phase 3Authorised
- Sponsor
- CHRU Nancy
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of regorafenib in metastatic colon cancer (mCRC) (2 arms), sponsored by CHRU Nancy. Planned start Dec 2024; status: authorised.
02
Drugs
regorafenib
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2024-516709-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516709-22-00.